In Q3 2026, teams using general-purpose AI models produced lab-confirmed protein binders at up to 3.5 times the industry hit rate, and big pharma signed to deploy agentic design tools at scale. Proving a drug works in humans stayed as slow and as expensive as before. Then Washington started pricing where that proof gets generated, in the same quarter the Phase III of the best-known AI-discovered drug started entirely at Chinese sites.